Latest Interferon Stories

Researchers targeted the type of hepatitis C most common in the United States, results reported in New England Journal of Medicine ANN ARBOR, Mich., Jan. 19, 2012 /PRNewswire-USNewswire/ -- A new combination of investigational drugs successfully suppressed hepatitis C genotype 1 infection in a high percent of patients who had not responded to previous treatment in a study led by a University of Michigan hepatologist. The study, published Jan. 19 in the New England Journal of...

Researchers targeted the type of hepatitis C most common in the United States, results reported in New England Journal of Medicine A new combination of investigational drugs successfully suppressed hepatitis C genotype 1 infection in a high percent of patients who had not responded to previous treatment in a study led by a University of Michigan hepatologist. The study, which will be published Jan. 19 in the New England Journal of Medicine, focused on hepatitis C genotype 1, which is...

CAMBRIDGE, Mass., Jan. 9, 2012 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced interim data from a 12-week phase IIb clinical trial of IDX184, the Company's lead product candidate for the treatment of hepatitis C virus (HCV) infection. IDX184, a pan-genotypic oral nucleotide polymerase inhibitor, has demonstrated a high barrier to...

PRINCETON, N.J., Dec. 16, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that the company will amend the design of the QUANTUM Phase 2b trial of the guanine nucleotide analog PSI-938 and discontinue all treatment arms with a regimen containing PSI-938. There are 235 individuals with hepatitis C virus (HCV) in the study who are receiving treatment with PSI-938 alone or in combination with PSI-7977 or PSI-7977 and ribavirin. During routine safety monitoring, the...

When the activity of a molecule that is normally elevated during viral infections is inhibited in the brain, mice learn and remember better, researchers at Baylor College of Medicine reported in a recent article in the journal Cell. "The molecule PKR (the double-stranded RNA-activated protein kinase) was originally described as a sensor of viral infections, but its function in the brain was totally unknown," said Dr. Mauro Costa-Mattioli, assistant professor of neuroscience at BCM and...

When the activity of a molecule that is normally elevated during viral infections is inhibited in the brain, mice learn and remember better, researchers at Baylor College of Medicine reported in a recent article in the journal Cell. "The molecule PKR (the double-stranded RNA-activated protein kinase) was originally described as a sensor of viral infections, but its function in the brain was totally unknown," said Dr. Mauro Costa-Mattioli, assistant professor of neuroscience at BCM and...

By Alicia Rose DelGallo, Ivanhoe Health Correspondent (Ivanhoe Newswire) – A memory-enhancing drug has been discovered unexpectedly by researchers at Baylor College of Medicine. When the activity of a molecule, normally elevated during viral infections, is inhibited, mice learn and remember better, a recent article in the Journal Cell reported. "PKR is a protein kinase which was originally described as a sensor of viral genome. We knew nothing about PKR’s role in brain processes,"...

PRINCETON, N.J., Nov. 14, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the fiscal year ended September 30, 2011. At fiscal year end Pharmasset held $166.5 million in cash and cash equivalents and used $21.7 million of our cash and cash equivalents during the fourth quarter of fiscal...

PRINCETON, N.J., Nov. 13, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces that management will present at the Lazard Capital Markets 8th Annual Healthcare Conference to be held November 15 to 16, 2011 at the Pierre Hotel, New York. Schaefer Price, Pharmasset's President and Chief Executive Officer, will provide an overview of the company on Tuesday, November 15 at 3:00 PM (ET). To access a simultaneous webcast of Mr. Price's overview via the internet, log on to the "Events...

At first it sounds like good news: The body's own immune system gets active in almost every cancer – however, not necessarily for the benefit of the patient. "We distinguish between two different types of immune response," says Professor Dr. Viktor Umansky, immunologist at DKFZ and University Medical Center Mannheim. "On the one hand, cells of the immune system specifically attack tumor cells. On the other, however, almost every tumor causes in its microenvironment a chronic inflammatory...